On Monday, Eli Lilly got an upgrade for its IBD SmartSelect Composite Rating from 87 to 97.
Lean How — And When — To Sell Stocks
The new score indicates the company is now outperforming 97% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
Eli Lilly is currently forming a double bottom, with a 935.63 entry. See if the stock can break out in volume at least 40% higher than normal.
The stock earns a 95 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 95% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q4, the company reported 114% EPS growth. Top line growth climbed 45%, up from 20% in the prior report. That marks one quarter of increasing revenue gains. The company's next quarterly report is expected on or around May. 1.
Eli Lilly holds the No. 1 rank among its peers in the Medical-Diversified industry group. AstraZeneca ADR and Abbott Laboratories are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
